Gene Logic and deSciner Enter into a Partnership to Create 'Genomics Gateway'

14-Oct-2008 - Gene Logic has entered into a Strategic Alliance with deSciner™ Business Network to create an interactive genomics information resource. Both organizations will work together to create a unique knowledge resource in genomics called 'Genomics Gateway'. The vision of this partnership is to present ...

Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's Disease

Results Predict Likelihood and Age of Disease Onset, May Lead to Risk-Assessment Tests

20-Jun-2007 - Gene Logic Inc. announced that a collaborative study between its Genomics Division and Mayo Clinic has found biomarkers that predict susceptibility to Parkinson's disease and age of disease onset. The study was novel in its detailed and comprehensive analysis of genes and their polymorphic ...

Gene Logic Provides the FDA with Access to Toxicogenomics Data and Analysis Systems

14-Aug-2006 - Gene Logic Inc. announced that it entered into an agreement with the United States Food and Drug Administration ("FDA") to provide the FDA with access to certain of Gene Logic's genomics data and software, including: - an extensive collection of toxicogenomics and rat classical toxicology data ...

Organon and Gene Logic enter collaboration to find new therapeutic applications for clinical drug candidates

25-Apr-2006 - Gene Logic Inc. and Organon announced that they have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon has previously discontinued clinical development. Under the terms of the agreement, Gene Logic will seek new ...

Gene Logic and Roche Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates

12-Dec-2005 - Gene Logic Inc. announced that it has entered into a drug repositioning and development agreement with Roche to seek alternative development paths for multiple Roche drug candidates. All of these drug candidates have successfully passed Phase I human clinical trials, and were discontinued in ...

Gene Logic Enters Agreement with Pfizer to Reposition Significant Number of Drug Candidates

29-Sep-2005 - Gene Logic Inc. announced that it has entered into an agreement with Pfizer Inc. to seek new therapeutic indications for a significant number of unapproved drug candidates that are not currently in active development. The drug candidates originated from across Pfizer's portfolio of therapeutic ...

Gene Logic Sees Growing Trend from Pharma Industry for Safety Testing

28-Feb-2005 - Gene Logic Inc. announced it has completed over 350 predictive toxicity assessments, using its proprietary toxicogenomics predictive models, on clients' live compounds, failed drugs and reference compounds profiled in various organ systems and primary rat hepatocytes. This genomics-based safety ...

Gene Logic K.K. Officially Opens Office in Japan

Local Presence to Meet the Needs of Japanese Pharmaceutical Customers

17-Nov-2004 - Gene Logic Inc. announced that it's wholly owned Japan subsidiary, Gene Logic K.K., has officially opened its offices in Japan to more closely provide sales support and customer service to pharmaceutical customers in Japan. The Company has located its offices in downtown Tokyo, hired two ...

Gene Logic Expands International Operations - Establishes Staff in UK and Germany

Forms Gene Logic K.K. to Serve Japanese Market

19-Aug-2004 - Gene Logic Inc. announced the expansion of its European and Asia Pacific operations. Gene Logic has added sales and support staff to its European office, Gene Logic Ltd., based in London, and also hired a business development representative who will be based in Germany. In addition, the Company ...

Gene Logic to Establish UK-Based Subsidiary - Gene Logic Ltd

Continues Expansion of Global Pharmacogenomics Services with EU Staff

11-Mar-2004 - Gene Logic Inc. announced that it has established Gene Logic Ltd., a wholly owned subsidiary based in the United Kingdom, that will facilitate sales, marketing and customer support in Europe for the Company's full range of genomic-based services beginning in March 2004. The move will enable Gene ...